TAK-676 + carboplatin + paclitaxel

TAK-676 + carboplatin + paclitaxel is a combination investigational regimen composed of three agents: **TAK-676**, a novel systemic small-molecule stimulator of interferon genes (**STING**) pathway agonist, along with chemotherapeutic agents **carboplatin** and **paclitaxel**. TAK-676 is designed to activate the innate immune response and stimulate antitumor activity by triggering the STING signaling pathway, resulting in increased production of type I interferons and activation of immune cells, including dendritic cells, natural killer cells, and T cells, within the tumor microenvironment. **Carboplatin** and **paclitaxel** are established cytotoxic chemotherapies commonly used together in the treatment of various solid tumors, acting primarily through DNA crosslinking (carboplatin) and microtubule inhibition (paclitaxel), leading to tumor cell death. The combination is being clinically investigated for synergistic antitumor effects in advanced malignancies, leveraging both immunomodulation and direct cytotoxicity[1].